DRG Epidemiology's coverage of psoriasis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world.

DRG Epidemiology's PsO forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PsO over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following PsO subpopulation:

  • Diagnosed prevalent cases.

Note: Coverage may vary by country.

Table of contents

  • Psoriasis - Epidemiology - Middle East & Africa
    • Introduction
      • Key Findings
      • Key Updates
      • Prevalence of Psoriasis per 1,000 Among People of All Ages in 2019 and 2029
      • Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Psoriasis Over the Next 10 Years
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases
      • Diagnosed Prevalent Cases
      • Diagnosed Prevalent Cases by Severity
      • Diagnosed Prevalent Cases by Subtype
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Psoriasis
        • Studies Excluded from the Analysis of Psoriasis
      • Risk/Protective Factors
        • Risk/Protective Factors for Psoriasis
      • Bibliography
        • Glossary

    Author(s): T.J. Arndt, MPH, CPH; Nicole Zhang, MPH

    T.J. joined Decision Resources Group in 2018 as an entry-level epidemiologist and previously worked in basic sciences research academia.

    T.J. earned his Masters in Public Health from the University of Florida, where he conducted an internship focused on developing a clinical model to non-invasively screen for Non-Alcoholic Steatohepatitis (NASH). He also holds a B.S. in Microbiology & Cell Science and a B.A. in Spanish, both from the University of Florida. During his undergraduate and graduate career, he worked in two physiology-based research labs at the University of Florida, focusing on maternal and fetal stresses during pregnancy and parturition.

    Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders.

    She holds an M.P.H. from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a B.A. in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.


    Related Reports

    Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

    The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF

    View Details

    Psoriasis - Current Treatment - Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

    Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management o...

    View Details

    Psoriasis | Disease Landscape and Forecast | G7 | 2020

    The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier posit...

    View Details

    Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

    Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

    View Details